Filing Flows › Recursion Pharmaceuticals (RXRX) › Recalls, complaints & regulation
Recursion Pharmaceuticals (RXRX): clinical trials
Recursion Pharmaceuticals (RXRX) beyond its filings: 3 active clinical trials.
Recursion Pharmaceuticals' latest quarter
Recursion Pharmaceuticals, Q3 2026: revenue $18.6M (+258% year over year), operating margin -663.9%, net loss $119M, operating cash flow −$77.4M. The chart follows the revenue to costs, profit and cash.
Questions
How many clinical trials does Recursion Pharmaceuticals have?
3 active studies on ClinicalTrials.gov, 0 in phase 3.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.